BioMerieux SA
BIM: XPAR (FRA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| lqD | LOCK|jk%!W | LOCK|?r>M?v |
BioMérieux Earnings: Weak Respiratory Season Weighs on Sales; Shares Fairly Valued
BioMérieux reported 3.1% organic sales growth during the third quarter. Nonrespiratory molecular growth was partially offset by lower respiratory pathogen circulation and currency effects.
